{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:59:47Z","timestamp":1762145987519,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.yexmp.2012.01.007","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T15:31:25Z","timestamp":1328023885000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-na\u00efve and -exposed Southeast Asian chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"92","author":[{"given":"Wanwisa","family":"Wongboonma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanna","family":"Thongnoppakhun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirayu U.","family":"Auewarakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2012.01.007_bb0005","first-page":"2122","article-title":"The M351T BCR-ABL kinase mutation is uncommon in Asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels","volume":"112","author":"Ang","year":"2008"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0010","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0015","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000093641","article-title":"Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants","volume":"116","author":"Auewarakul","year":"2006","journal-title":"Acta Haematologica"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0020","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0025","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nrclinonc.2010.151","article-title":"Hematology: nilotinib and dasatinib\u2014new \u2018magic bullets\u2019 for CML?","volume":"7","author":"Breccia","year":"2010","journal-title":"Nature Reviews. Clinical Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/10428190903503446","article-title":"Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia","volume":"51","author":"Carella","year":"2010","journal-title":"Leukemia & Lymphoma."},{"key":"10.1016\/j.yexmp.2012.01.007_bb0035","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0045","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1182\/blood-2002-12-3659","article-title":"Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib","volume":"101","author":"Corbin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0040","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0050","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.leu.2403307","article-title":"Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography","volume":"18","author":"Deininger","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nm1009-1149","article-title":"Perspectives on the development of imatinib and the future of cancer research","volume":"15","author":"Druker","year":"2009","journal-title":"Nature Medicine"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0060","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3324\/haematol.11993","article-title":"Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0065","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3324\/haematol.12964","article-title":"ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia","volume":"93","author":"Ernst","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0070","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia","volume":"137","author":"Giralt","year":"2007","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0075","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/leu.2010.179","article-title":"Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype","volume":"24","author":"Grant","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0080","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0085","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2002-06-1756","article-title":"Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia","volume":"102","author":"Hofmann","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0090","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0095","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0110","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.25656","article-title":"Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0100","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.25717","article-title":"Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia","volume":"117","author":"Jabbour","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0115","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells","volume":"99","author":"Jiang","year":"2007","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2353\/jmoldx.2009.080095","article-title":"Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology","volume":"11","author":"Jones","year":"2009","journal-title":"Journal of Molecular Diagnostics"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0120","doi-asserted-by":"crossref","first-page":"5428","DOI":"10.1182\/blood-2009-11-252155","article-title":"Uncommon BCR-ABL kinase domain mutations in kinase inhibitor resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0130","first-page":"659","article-title":"Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib","volume":"91","author":"Kang","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/hon.894","article-title":"Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent","volume":"27","author":"Kim","year":"2009","journal-title":"Hematological Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0140","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s00277-003-0644-y","article-title":"Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique","volume":"82","author":"Kreuzer","year":"2003","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0145","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/10428190802714032","article-title":"Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India","volume":"50","author":"Kuila","year":"2009","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Ros\u00e9e","year":"2010","journal-title":"Seminars in Hematology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","article-title":"Resistance to imatinib mesylate in chronic myeloid leukaemia","volume":"249","author":"Melo","year":"2007","journal-title":"Cancer Letters"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2008-05-158535","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0165","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0170","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.21380","article-title":"First-line therapy for chronic myeloid leukemia: past, present, and future","volume":"84","author":"Pavlovsky","year":"2009","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0175","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0180","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1182\/blood-2008-08-173674","article-title":"Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib","volume":"114","author":"Press","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0185","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-010-1039-5","article-title":"Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients","volume":"90","author":"Qin","year":"2011","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0190","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of BCR-ABL1-positive chronic myeloid leukemia","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0195","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10428190903437629","article-title":"Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate","volume":"51","author":"Rajappa","year":"2010","journal-title":"Leukemia & Lymphoma."},{"key":"10.1016\/j.yexmp.2012.01.007_bb0205","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0200","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMc035089","article-title":"A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia","volume":"348","author":"Roche-Lestienne","year":"2003","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0210","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0215","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2010.159","article-title":"Insights into the stem cells of chronic myeloid leukemia","volume":"24","author":"Sloma","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0220","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0225","doi-asserted-by":"crossref","first-page":"400","DOI":"10.4161\/cc.4.3.1560","article-title":"A cell-based screening strategy that predicts mutations in oncogenic tyrosine kinases: implications for clinical resistance in targeted cancer treatment","volume":"4","author":"von Bubnoff","year":"2005","journal-title":"Cell Cycle"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0230","series-title":"Molecular Biomethods Handbook","first-page":"89","article-title":"Denaturing high-performance liquid chromatography (DHPLC) for nucleic acid analysis","author":"Walker","year":"2008"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0235","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1756-8722-3-47","article-title":"First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib","volume":"3","author":"Wei","year":"2010","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0240","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","article-title":"High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy","volume":"106","author":"Willis","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.yexmp.2012.01.007_bb0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-8722-4-7","article-title":"A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients","volume":"4","author":"Wongboonma","year":"2011","journal-title":"Journal of Hematology & Oncology"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480012000147?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480012000147?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:58:30Z","timestamp":1762145910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480012000147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0014480012000147"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2012.01.007","relation":{},"ISSN":["0014-4800"],"issn-type":[{"type":"print","value":"0014-4800"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-na\u00efve and -exposed Southeast Asian chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2012.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}